3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1/2
4
Phase NA
2
Phase 4
1
Phase 3
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
19
Tumor-Agnostic
11
Head & Neck
11
Genitourinary
11
Gastrointestinal
11
Gynecologic
6
Breast
3
Endocrine
1
Classical hematology
1
Conditions
Neuroendocrine Tumors
32
Multiple Endocrine Neoplasia Type 1
9
Neoplasms
8
Pituitary Neoplasms
7
Carcinoid Tumor
7
Pituitary ACTH Hypersecretion
6
Gastro-enteropancreatic neuroendocrine tumor
6
Differentiated Thyroid Cancer
6
Adrenocortical Carcinoma
6
Thyroid Cancer, Papillary
5
Pituitary Diseases
5
Pheochromocytoma
5
Thyroid Neoplasms
4
Serotonin Syndrome
4
Neuroblastoma
4
Cushing Syndrome
4
Breast Neoplasms
4
Acromegaly
4
ACTH Syndrome, Ectopic
4
Sarcoma
3
Liposarcoma
3
Insulinoma
3
Fibrosarcoma
3
Endometrial Neoplasms
3
Carcinoma, Medullary
3
Adenoma, Islet Cell
3
Adenocarcinoma, Follicular
3
Sarcoma, Synovial
2
Sarcoma, Endometrial Stromal
2
Parkinson Disease
2
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Endocrine
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts